Hills M - Search Results

1

Detre S, Salter J, Barnes DM, Riddler S, Hills M, Johnston SR, Gillett C, A'Hern R, Dowsett M. Detre S, et al. Among authors: hills m. Int J Cancer. 1999 Apr 12;81(2):309-13. doi: 10.1002/(sici)1097-0215(19990412)81:2<309::aid-ijc23>3.0.co;2-s. Int J Cancer. 1999. PMID: 10188736 Free article.

2

Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer.

Dowsett M, Dixon JM, Horgan K, Salter J, Hills M, Harvey E. Dowsett M, et al. Among authors: hills m. Clin Cancer Res. 2000 Jun;6(6):2260-7. Clin Cancer Res. 2000. PMID: 10873076 Clinical Trial.

3

Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients.

Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, Cohen FJ, Veronesi P, O'Brien ME, Scott T, Muchmore DB. Dowsett M, et al. Among authors: hills mj. Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):961-6. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11535548 Clinical Trial.

4

HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.

Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, Smith I. Dowsett M, et al. Among authors: hills m. Cancer Res. 2001 Dec 1;61(23):8452-8. Cancer Res. 2001. PMID: 11731427

5

Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.

Harper-Wynne CL, Sacks NP, Shenton K, MacNeill FA, Sauven P, Laidlaw IJ, Rayter Z, Miall S, Howes A, Salter J, Hills MJ, Lowe FM, A'Hern R, Nasiri N, Doody D, Iqbal J, Dowsett M. Harper-Wynne CL, et al. Among authors: hills mj. J Clin Oncol. 2002 Feb 15;20(4):1026-35. doi: 10.1200/JCO.2002.20.4.1026. J Clin Oncol. 2002. PMID: 11844826 Clinical Trial.

6

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, Watters AD, Cooke T, Paish C, Wencyk PM, Pinder SE. Dowsett M, et al. Among authors: hills m. J Pathol. 2003 Apr;199(4):418-23. doi: 10.1002/path.1313. J Pathol. 2003. PMID: 12635131

7

Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer.

Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M. Davies G, et al. Among authors: hills m. Clin Cancer Res. 2003 Jul;9(7):2651-6. Clin Cancer Res. 2003. PMID: 12855643

8

High incidence of HER-2 positivity in inflammatory breast cancer.

Parton M, Dowsett M, Ashley S, Hills M, Lowe F, Smith IE. Parton M, et al. Among authors: hills m. Breast. 2004 Apr;13(2):97-103. doi: 10.1016/j.breast.2003.08.004. Breast. 2004. PMID: 15019688

9

Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status.

Dixon JM, Jackson J, Hills M, Renshaw L, Cameron DA, Anderson TJ, Miller WR, Dowsett M. Dixon JM, et al. Among authors: hills m. Eur J Cancer. 2004 Dec;40(18):2742-7. doi: 10.1016/j.ejca.2004.08.025. Eur J Cancer. 2004. PMID: 15571956 Clinical Trial.

10

Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.

Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G; IMPACT Trialists. Dowsett M, et al. Among authors: hills m. Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):951s-8s. Clin Cancer Res. 2005. PMID: 15701892 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

241 results

Search Page